AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35654318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 33725852 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary IL-1β levels
Number of subjects: 111
Study 33725852 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary MIF levels
Number of subjects: 111
Study 33725852 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding Index
Number of subjects: 111
Study 33784411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroids (INCS) - triamcinolone acetonide (220µg)
Number of subjects: 10
Study 33784411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 32893024 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacutaneous Fibrolysis (DF)
Number of subjects: 34
Study 32893024 — intervention group
Group type: COMPARATOR
Intervention: Sham Diacutaneous Fibrolysis (sham-DF)
Number of subjects: 34
Study 34255874 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiPoint pacing (MPP)
Number of subjects: 49
Study 34255874 — intervention group
Group type: COMPARATOR
Intervention: BiV therapy
Number of subjects: 49
Study 32265363 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO)
Number of subjects: 76
Study 32265363 — intervention group
Group type: COMPARATOR
Intervention: Low-flow nasal oxygen (LFNO)
Number of subjects: 76
Study 34491513 — intervention group
Group type: COMPARATOR
Intervention: MD (220 mg/m2)
Number of subjects: 136
Study 34491513 — intervention group
Group type: COMPARATOR
Intervention: LD (180 mg/m2)
Number of subjects: 136
Study 34491513 — intervention group
Group type: EXPERIMENTAL
Intervention: SD (260 mg/m2)
Number of subjects: 136
Study 34798892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry supplementation (144 mg capsule)
Number of subjects: 110
Study 34798892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 35092535 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel with bevacizumab (CPB)
Number of subjects: 16
Study 35092535 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel alone (CP)
Number of subjects: 16
Study 32979387 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged PDA exposure (≥11 days) in infants requiring intubation for ≥10 days
Number of subjects: 0
Study 32979387 — intervention group
Group type: COMPARATOR
Intervention: Infants requiring <10 days of intubation
Number of subjects: 0
Study 36071630 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast density notification with health literacy-sensitive information
Number of subjects: 940
Study 36071630 — intervention group
Group type: COMPARATOR
Intervention: Breast density notification without health literacy-sensitive information
Number of subjects: 940
Study 33040600 — intervention group
Group type: EXPERIMENTAL
Intervention: mPCNL
Number of subjects: 60
Study 33040600 — intervention group
Group type: COMPARATOR
Intervention: SPCNL
Number of subjects: 60
Study 32250330 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (T) therapy
Number of subjects: 22
Study 32250330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 35728921 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 250-mg tablet manufactured at Pfizer Dalian (China)
Number of subjects: 0
Study 35728921 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 250-mg tablet manufactured at Pfizer Barceloneta (United States)
Number of subjects: 0
Study 35728921 — intervention group
Group type: COMPARATOR
Intervention: Fasted condition
Number of subjects: 0
Study 35728921 — intervention group
Group type: COMPARATOR
Intervention: Fed condition
Number of subjects: 0
Study 32903168 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon angioplasty
Number of subjects: 95
Study 32903168 — intervention group
Group type: COMPARATOR
Intervention: Plain old balloon angioplasty (POBA)
Number of subjects: 95
Study 32157686 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education and medical nutrition therapy (MNT) sessions provided within 1-2 weeks of GDM diagnosis.
Number of subjects: 0
Study 32157686 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing management through GDM clinic or step-up/step-down approaches.
Number of subjects: 0
Study 32157686 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth services to reduce clinic attendance burden.
Number of subjects: 0
Study 35260388 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-guided therapy withdrawal (based on S100A12 and hsCRP levels)
Number of subjects: 119
Study 35260388 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing therapy due to elevated S100A12/hsCRP levels
Number of subjects: 119
Study 35260388 — intervention group
Group type: COMPARATOR
Intervention: Control group (BiKeR registry, therapy withdrawal without biomarker-based stratification)
Number of subjects: 119
Study 35260388 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-guided therapy withdrawal
Number of subjects: 119
Study 35921872 — intervention group
Group type: EXPERIMENTAL
Intervention: Estetrol (E4) 15 mg/drospirenone (DRSP) 3 mg in a 24/4‐day regimen
Number of subjects: 3409
Study 34893062 — intervention group
Group type: EXPERIMENTAL
Intervention: DA‐3002 (Growtropin®‐II) at 0.14 IU/kg/day
Number of subjects: 58
Study 34893062 — intervention group
Group type: COMPARATOR
Intervention: Comparator (Genotropin®) at 0.14 IU/kg/day
Number of subjects: 58
Study 34893062 — intervention group
Group type: EXPERIMENTAL
Intervention: DA‐3002 (Growtropin®‐II)
Number of subjects: 58
Study 34893062 — intervention group
Group type: COMPARATOR
Intervention: Comparator (Genotropin®)
Number of subjects: 58
Study 32511726 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based CBT-I program (SHUTi)
Number of subjects: 303
Study 32511726 — intervention group
Group type: COMPARATOR
Intervention: Internet-based patient education (PE)
Number of subjects: 303
Study 35320161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus over 10 min, followed by 1.5 mg/kg/h infusion for 24 hours)
Number of subjects: 90
Study 35320161 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo administered at the same rate as lidocaine)
Number of subjects: 90
Study 33109923 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 53
Study 33109923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 32473046 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 133
Study 32473046 — intervention group
Group type: COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV23)
Number of subjects: 133
Study 35787943 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan (50 mg tablet, once daily) and Naproxen (500 mg tablet, twice daily)
Number of subjects: 46
Study 35787943 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan and Aceclofenac (100 mg tablet, twice daily)
Number of subjects: 46
Study 35787943 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan and Celecoxib (200 mg capsule, twice daily)
Number of subjects: 46
Study 34187840 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast fluid infusion (0.90% saline)
Number of subjects: 714
Study 34187840 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.90% saline
Number of subjects: 714
Study 34187840 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45% saline
Number of subjects: 714
Study 34187840 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast fluid infusion
Number of subjects: 714
Study 34187840 — intervention group
Group type: COMPARATOR
Intervention: Slow fluid infusion
Number of subjects: 714
Study 36012011 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST) twice a week at 75% intensity of one‐repetition maximum for 10 weeks during winter
Number of subjects: 18
Study 36012011 — intervention group
Group type: COMPARATOR
Intervention: Control group (CT) that did not perform ST
Number of subjects: 18
Study 35446449 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session family behavioral intervention (FBI)
Number of subjects: 94
Study 35446449 — intervention group
Group type: COMPARATOR
Intervention: Crossover group (received FBI in the second 6-months)
Number of subjects: 94
Study 32026701 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated transitional care program (ongoing rehabilitation at home through multidisciplinary team)
Number of subjects: 98
Study 32026701 — intervention group
Group type: COMPARATOR
Intervention: Secondary stroke prevention (control group)
Number of subjects: 98
Study 35645037 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg cefuroxime sodium plus 500 mg intravenous azithromycin (experimental group)
Number of subjects: 242
Study 35645037 — intervention group
Group type: COMPARATOR
Intervention: 1500 mg cefuroxime sodium plus placebo (placebo group)
Number of subjects: 242
Study 33853037 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy (experimental therapy)
Number of subjects: 0
Study 33853037 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing risk analyses
Number of subjects: 0
Study 33853037 — intervention group
Group type: COMPARATOR
Intervention: Kaplan-Meier (KM) methods
Number of subjects: 0
Study 33259240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of hyaluronic acid with intradetrusor botulinum toxin A (BTX‐A) injection
Number of subjects: 36
Study 33259240 — intervention group
Group type: COMPARATOR
Intervention: Cystoscopic hydrodistention
Number of subjects: 36
Study 35439645 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 207
Study 35439645 — intervention group
Group type: COMPARATOR
Intervention: Control (no estrogen therapy)
Number of subjects: 207
Study 34769896 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week guided recreational skiing program (average of 28.5 ± 2.6 skiing days)
Number of subjects: 48
Study 32105387 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar intrathecal fentanyl (FENT)
Number of subjects: 16
Study 32105387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study 35979703 — intervention group
Group type: EXPERIMENTAL
Intervention: EES + PFMT
Number of subjects: 51
Study 35979703 — intervention group
Group type: COMPARATOR
Intervention: PFMT
Number of subjects: 51
Study 35979703 — intervention group
Group type: COMPARATOR
Intervention: EES
Number of subjects: 51
Study 33525419 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral probiotic Weissella cibaria CMU
Number of subjects: 0
Study 33525419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35964961 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Optometry application
Number of subjects: 100
Study 35964961 — intervention group
Group type: COMPARATOR
Intervention: Conventional distance VA chart screening
Number of subjects: 100
Study 35964961 — intervention group
Group type: COMPARATOR
Intervention: Near vision E chart
Number of subjects: 100
Study 34684621 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g MSM daily for 16 weeks
Number of subjects: 22
Study 34684621 — intervention group
Group type: COMPARATOR
Intervention: Placebo (white rice flour)
Number of subjects: 22
Study 32697532 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast angiosarcoma patients
Number of subjects: 13
Study 32697532 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who died
Number of subjects: 13
Study 36321379 — intervention group
Group type: EXPERIMENTAL
Intervention: nCRT (neoadjuvant chemoradiotherapy)
Number of subjects: 327
Study 36321379 — intervention group
Group type: COMPARATOR
Intervention: nCT (chemotherapy)
Number of subjects: 327
Study 36321379 — intervention group
Group type: EXPERIMENTAL
Intervention: nCRT
Number of subjects: 327
Study 36321379 — intervention group
Group type: COMPARATOR
Intervention: nCT
Number of subjects: 327
Study 33656542 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined division of the splenic vein
Number of subjects: 316
Study 33656542 — intervention group
Group type: COMPARATOR
Intervention: Separate division of the splenic vein
Number of subjects: 316
Study 32908007 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Roseomonas mucosa
Number of subjects: 15
Study 35987213 — intervention group
Group type: EXPERIMENTAL
Intervention: saccharin
Number of subjects: 120
Study 35987213 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralose
Number of subjects: 120
Study 35987213 — intervention group
Group type: EXPERIMENTAL
Intervention: aspartame
Number of subjects: 120
Study 35987213 — intervention group
Group type: EXPERIMENTAL
Intervention: stevia
Number of subjects: 120
Study 35987213 — intervention group
Group type: COMPARATOR
Intervention: vehicle glucose or no supplement
Number of subjects: 120
Study 34331186 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS (computer-assisted 3D measurement system)
Number of subjects: 63
Study 34331186 — intervention group
Group type: EXPERIMENTAL
Intervention: PT (premeasured tape)
Number of subjects: 63
Study 34331186 — intervention group
Group type: COMPARATOR
Intervention: VJ (visual judgment)
Number of subjects: 63
Study 34331186 — intervention group
Group type: EXPERIMENTAL
Intervention: IM (instrument markings)
Number of subjects: 63
Study 34331186 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS
Number of subjects: 63
Study 34331186 — intervention group
Group type: EXPERIMENTAL
Intervention: PT
Number of subjects: 63
Study 34331186 — intervention group
Group type: COMPARATOR
Intervention: VJ
Number of subjects: 63
Study 34331186 — intervention group
Group type: EXPERIMENTAL
Intervention: IM
Number of subjects: 63
Study 33399530 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat
Number of subjects: 70
Study 33399530 — intervention group
Group type: COMPARATOR
Intervention: Leaflet
Number of subjects: 70
Study 35817498 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS)
Number of subjects: 45
Study 35817498 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 45
Study 33872583 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline bitartrate supplements (n = 20)
Number of subjects: 82
Study 33872583 — intervention group
Group type: COMPARATOR
Intervention: Hardboiled eggs (n = 18)
Number of subjects: 82
Study 33872583 — intervention group
Group type: EXPERIMENTAL
Intervention: Hardboiled eggs + choline bitartrate supplements (n = 16)
Number of subjects: 82
Study 33872583 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg whites + choline bitartrate supplements (n = 18)
Number of subjects: 82
Study 33872583 — intervention group
Group type: COMPARATOR
Intervention: Phosphatidylcholine supplements (n = 10)
Number of subjects: 82
Study 32810220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (1000 mg)
Number of subjects: 438
Study 32810220 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (375 mg/m2)
Number of subjects: 438
Study 36431201 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized punicalagin enriched oral pomegranate extract (Pomella®) daily for four weeks
Number of subjects: 0
Study 36431201 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 34053748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral regimen causing moderate nausea
Number of subjects: 123
Study 34053748 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly IV regimen causing mild memory problems
Number of subjects: 123
Study 34053748 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly IV regimen causing mild memory and mild neuropathy
Number of subjects: 123
Study 34053748 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate neuropathy
Number of subjects: 123
Study 34053748 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year PFS
Number of subjects: 123
Study 34053748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost
Number of subjects: 123
Study 34053748 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month PFS
Number of subjects: 123
Study 34053748 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathy
Number of subjects: 123
Study 34053748 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory problems
Number of subjects: 123
Study 34053748 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea
Number of subjects: 123
Study 34053748 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen
Number of subjects: 123
Study 34667864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin-soaked gelfoam
Number of subjects: 100
Study 34667864 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone-soaked gelfoam
Number of subjects: 100
Study 36248820 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention for 12 weeks
Number of subjects: 40
Study 36248820 — intervention group
Group type: COMPARATOR
Intervention: Control group (NG)
Number of subjects: 40
Study 32465484 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPSE/sPAP (T/P)
Number of subjects: 205
Study 32465484 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 205
Study 32465484 — intervention group
Group type: EXPERIMENTAL
Intervention: RV‐MPI
Number of subjects: 205
Study 32465484 — intervention group
Group type: EXPERIMENTAL
Intervention: TRG
Number of subjects: 205
Study 34437072 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Robust Semisupervised Variational Autoencoder Generative Adversarial Network (URSVAE-GAN)
Number of subjects: 0
Study 34437072 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Robust Semisupervised Variational Autoencoder (URSVAE)
Number of subjects: 0
Study 34437072 — intervention group
Group type: EXPERIMENTAL
Intervention: Denoising layer integrated into URSVAE
Number of subjects: 0
Study 34437072 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust ?-divergence measure
Number of subjects: 0
Study 32967068 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D (ergocalciferol) at 40,000 IU per week
Number of subjects: 80
Study 32967068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 35964356 — intervention group
Group type: EXPERIMENTAL
Intervention: EXP (Stroop task)
Number of subjects: 20
Study 35964356 — intervention group
Group type: COMPARATOR
Intervention: CON (documentary)
Number of subjects: 20
Study 32405570 — intervention group
Group type: EXPERIMENTAL
Intervention: High NO3− (140 ml of beetroot juice (BJ) per day, 800 mg of NO3−/day)
Number of subjects: 60
Study 32405570 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate NO3− (70 ml of BJ per day, 400 mg of NO3−/day)
Number of subjects: 60
Study 32405570 — intervention group
Group type: EXPERIMENTAL
Intervention: Low NO3− (70 ml on alternate days, 400 mg of NO3−)
Number of subjects: 60
Study 32405570 — intervention group
Group type: COMPARATOR
Intervention: NO3− depleted (70 ml on alternate days, 0.001 mg of NO3)
Number of subjects: 60
Study 33639543 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart-focused breathing protocol (10 minutes daily for 2 weeks)
Number of subjects: 10
Study 33639543 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 10
Study 32375661 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital reminiscence therapy (digital RT), 8 sessions over 4 weeks.
Number of subjects: 49
Study 32375661 — intervention group
Group type: COMPARATOR
Intervention: Conventional reminiscence therapy (storytelling, control group), 8 sessions over 4 weeks.
Number of subjects: 49
Study 36050872 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) mouthwash
Number of subjects: 45
Study 36050872 — intervention group
Group type: EXPERIMENTAL
Intervention: Manuka mouthwash
Number of subjects: 45
Study 36050872 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-Dental mouthwash
Number of subjects: 45
Study 32815384 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN)
Number of subjects: 80
Study 32815384 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy treatment
Number of subjects: 80
Study 35228288 — intervention group
Group type: EXPERIMENTAL
Intervention: PERFECT‐ER, an enhanced recovery pathway with 15 quality targets supported by a checklist and manual, a service improvement lead, a process lead, implemented using a plan‐do‐study‐act model.
Number of subjects: 284
Study 35228288 — intervention group
Group type: COMPARATOR
Intervention: Standard acute hospital care (control group).
Number of subjects: 284
Study 34747925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 40
Study 34747925 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 40
Study 34747925 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Ivabradine and Bisoprolol
Number of subjects: 40
Study 35867685 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose
Number of subjects: 58
Study 35867685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 34183510 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-antibiotic treatment (anti-inflammatory and symptomatic treatment)
Number of subjects: 480
Study 34183510 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic treatment (875/125 mg/8 h amoxicillin/clavulanic acid)
Number of subjects: 480
Study 32546645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 615
Study 34102933 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional abuse
Number of subjects: 518
Study 34102933 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical abuse
Number of subjects: 518
Study 34102933 — intervention group
Group type: EXPERIMENTAL
Intervention: Neglect
Number of subjects: 518
Study 34102933 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 518
Study 34102933 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal level of education
Number of subjects: 518
Study 34102933 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily screen time
Number of subjects: 518
Study 34102933 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco smoking
Number of subjects: 518
Study 34102933 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally maltreated and neglected participants
Number of subjects: 518
Study 32928045 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 146
Study 32928045 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 146